Author | David P. Kelsen, MD

Articles

Commentary (Kelsen): Adjuvant Therapy for Colorectal Cancer

April 17, 2006

Colon cancer remains one of the most common human malignancies, with an annual global incidence of slightly less than 1 million patients per year.

Commentary (Kelsen): Novel Vaccines for the Treatment of Gastrointestinal Cancers

November 01, 2005

ByDavid P. Kelsen, MD

Dr. Marshall has written a clearand concise review of the rationalefor and preliminarydata from studies using therapeuticvaccines in patients with establishedgastrointestinal (GI) malignancies.He has summarized the recent advancesleading to a better understandingof basic immunology. These have hadan important influence on the possibilitythat an effective therapeutic vaccineor vaccines can be developed.

Chemotherapy for Resectable and Advanced Pancreatic Cancer

October 01, 2001

ByEileen M. O'Reilly, MD|David P. Kelsen, MD

This article will review the pertinent data on the use of chemotherapy for all stages of pancreatic cancer. For patients with metastatic disease, fluorouracil (5-FU) was the standard of care for several decades until a single

Irinotecan and Cisplatin in Upper Gastrointestinal Malignancies

August 01, 1998

ByPeter C. Enzinger, MD|David H. Ilson, MD, PhD|Leonard B. Saltz, MD|Eileen M. O'Reilly, MD|David P. Kelsen, MD

Irinotecan (Camptosar), an active agent in the treatment of fluorouracil-refractory colorectal cancer, has antitumor activity in upper gastrointestinal cancers. Clinical trials from Japan indicate antitumor responses in gastric and